- Report
- January 2026
- 185 Pages
Global
From €3434EUR$3,939USD£2,986GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2432EUR$2,789USD£2,115GBP
- Report
- September 2025
- 142 Pages
Global
From €3500EUR$4,300USD£3,150GBP
- Report
- October 2025
- 456 Pages
Global
From €4316EUR$4,950USD£3,753GBP
- Report
- May 2025
- 200 Pages
Global
From €2171EUR$2,490USD£1,888GBP
- Report
- August 2025
- 180 Pages
Global
From €3434EUR$3,939USD£2,986GBP
- Report
- January 2026
- 187 Pages
Global
From €3434EUR$3,939USD£2,986GBP
- Report
- August 2025
- 192 Pages
Global
From €3434EUR$3,939USD£2,986GBP
- Report
- August 2025
- 193 Pages
Global
From €3434EUR$3,939USD£2,986GBP
- Report
- September 2025
- 250 Pages
Global
From €3915EUR$4,490USD£3,404GBP
- Report
- September 2025
- 250 Pages
Global
From €3915EUR$4,490USD£3,404GBP
- Report
- April 2025
- 200 Pages
Global
From €3915EUR$4,490USD£3,404GBP
- Report
- February 2026
- 362 Pages
Global
From €5101EUR$5,850USD£4,435GBP
- Report
- February 2026
- 196 Pages
Global
From €5101EUR$5,850USD£4,435GBP
- Report
- August 2025
- 190 Pages
Global
From €3434EUR$3,939USD£2,986GBP
- Drug Pipelines
- April 2025
- 240 Pages
Global
From €2616EUR$3,000USD£2,275GBP
- Report
- February 2026
- 381 Pages
Global
From €5101EUR$5,850USD£4,435GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2432EUR$2,789USD£2,115GBP
- Report
- June 2025
- 400 Pages
Global
From €4315EUR$4,949USD£3,752GBP
- Report
- August 2025
- 150 Pages
Global
From €3357EUR$3,850USD£2,919GBP
€4229EUR$4,850USD£3,677GBP

The Type 2 Diabetes Drug market is a subset of the Endocrine and Metabolic Disorders Drugs market. These drugs are used to treat Type 2 Diabetes, a chronic condition in which the body does not produce enough insulin or is unable to use insulin properly. Type 2 Diabetes Drugs are used to help control blood sugar levels, reduce the risk of complications, and improve overall health. These drugs can be taken orally, injected, or inhaled. Common Type 2 Diabetes Drugs include Metformin, Sulfonylureas, Thiazolidinediones, Meglitinides, DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors.
Some companies in the Type 2 Diabetes Drug market include Novo Nordisk, Sanofi, Eli Lilly, Merck, AstraZeneca, Boehringer Ingelheim, and Takeda. Show Less Read more